GlassScriptPhysician profile
Hannah Reece Robinson
NPI 1881317196
$1,570.03
in general payments reported to CMS, 2019-2025
22 companies · $487 in 2025
The $487 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $100 · 2023: $525 · 2024: $458 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.54 | 2023-2025 | |
| Pfizer INC. | $114.65 | 2023-2025 | |
| Antares Pharma, INC. | $109.70 | 2024-2025 | Xyosted |
| Tris Pharma INC | $96.14 | 2024-2025 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $85.96 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $80.15 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $77.82 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $74.47 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Noven Therapeutics, LLC | $69.45 | 2024-2025 | Xelstrym |
| Bayer Healthcare Pharmaceuticals INC. | $46.28 | 2023 | Kerendia |
| Janssen Pharmaceuticals, INC | $46.02 | 2023 | Spravato |
| Merck Sharp & Dohme LLC | $31.71 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Gilead Sciences, INC. | $28.63 | 2025 | |
| Corcept Therapeutics | $24.32 | 2023 | Korlym |
| Edwards Lifesciences Corporation | $24.14 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $21.58 | 2023 | Apretude |
| Astellas Pharma US INC | $21.51 | 2023 | Veozah |
| Vivus LLC | $20.60 | 2023 | Qsymia |
| Azurity Pharmaceuticals, INC. | $19.10 | 2025 | Azmiro |
| Takeda Pharmaceuticals U.S.A., INC. | $16.80 | 2023 | Trintellix |
| Glaxosmithkline, LLC. | $16.38 | 2023 | Trelegy Ellipta, Shingrix |
| Medtronic, INC. | $14.67 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.